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ha
MaOBJECTIVES This prospective, observational study in 988 asymptomatic or symptomatic low-risk patients without
prior coronary artery disease was conducted to deﬁne the relative value of coronary artery calcium score (CACS), exercise
treadmill testing (ETT), and stress myocardial perfusion single-photon emission computed tomography (SPECT) variables
in predicting long-term risk stratiﬁcation.
BACKGROUND CACS, ETT, and stress myocardial perfusion SPECT results predict patients’ outcome. There are
currently no data comparing their relative value in long-term risk stratiﬁcation.
METHODS Patients were stratiﬁed by Framingham risk score (FRS), with a median follow-up of 6.9 years. Cardiac events
were deﬁned as a composite of cardiac death, nonfatal myocardial infarction, and the need for coronary revascularization.
Most patients (87%) were considered appropriate candidates for functional testing as deﬁned by current appropriate use
criteria.
RESULTS The long-term cardiac event ratewas 11.2% (1.6%per year). Multivariate risk predictors in all patients and in the
appropriateuse cohortwere abnormal SPECT (hazard ratio [HR]: 1.83 and 1.99), ETT ischemia (HR: 1.70and 1.76), decreasing
exercise capacity (HR: 1.11 and 1.17), decreasing Duke treadmill score (HR: 1.07 for both), and CACS severity (HR: 1.29 for
both), respectively. Throughout the 10-year follow-up, CACS improved risk prediction, with event rates ranging from0.6%
per year (CACS#10) to 3.7% per year (CACS>400) (p< 0.0001). CACS also improved risk prediction in all patients, in the
appropriate use cohort and among those with low-risk ETT and SPECT results (all, p < 0.001). Area under the receiver-
operating characteristic curvewas increasedwhen CACS variables (from0.63 to 0.70; p¼0.01) but not ETT variables (from
0.63 to 0.65) were added to FRS. Moreover, net reclassiﬁcation improvement was signiﬁcantly increased when CACS was
added to FRS þ functional variables in all patients and in the appropriate use cohort (both, p < 0.0001).
CONCLUSIONS CACS signiﬁcantly improved long-term risk stratiﬁcation beyond FRS, ETT, and SPECT results across
the spectrum of clinical risk and importantly even among those who are currently considered appropriate candidates for
functional testing or have low-risk functional test results. Our ﬁndings support CACS as a ﬁrst-line test over ETT or SPECT
for accurately assessing long-term risk in such patients. (J Am Coll Cardiol Img 2015;8:134–44) © 2015 by the American
College of Cardiology Foundation.m the *Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas; and the yHouston Methodist Research
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AB BR E V I A T I O N S
AND ACRONYM S
AER = annualized event rate
AUC = area under the receiver-
operating characteristic curve
CACS = coronary artery
calcium score
DTS = Duke treadmill score
ETT = exercise treadmill test
FRS = Framingham risk score
IDI = integrated discrimination
improvement
METs = metabolic
equivalents of task
NRI = net reclassiﬁcation
improvement
SPECT = single-photon
emission computed
graphy
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135T he coronary artery calcium score (CACS)severity has been reported to predict pa-tients’ cardiac outcomes (1,2), and CACS is
considered an appropriate test in asymptomatic pa-
tients at intermediate to high clinical risk for coronary
artery disease (CAD) (3,4). Likewise, exercise tread-
mill testing (ETT), performed with or without cardiac
imaging, identiﬁes those at high or low risk for mor-
tality on the basis of the presence of stress-induced
ischemia (5), peak exercise capacity (in metabolic
equivalents of task [METs]) (6,7), and Duke treadmill
score (DTS) (7,8). Current guidelines (3,9) and appro-
priate use criteria (4) support both ETT and stress
myocardial perfusion single-photon emission com-
puted tomography (SPECT) for evaluating risk in
selected asymptomatic patients with risk factors for
CAD. However, there are no studies addressing which
of these tests offer the most beneﬁt in CAD detection
and long-term risk stratiﬁcation.SEE PAGE 145The purpose of this study was to examine the
relative value of CACS, ETT, and SPECT in predicting
long-term risk stratiﬁcation in a large cohort of
generally asymptomatic patients who had all tests
performed within a close temporal period and who
were followed up for up to a decade.
METHODS
STUDY POPULATION. This substudy analyzed data
from a previously published prospective, observa-
tional follow-up trial in 1,175 predominantly middle-
aged (40 to 65 years) men and women who had both
CACS and stress SPECT performed for clinically indi-
cated reasons (10). All patients had risk factors for, but
no history of, CAD. The substudy included 988 patients
(84%) who were stressed with ETT during SPECT (10).
CACS was performed as the ﬁrst-line test in 84% and
SPECT in 16% of patients who were either asymptom-
atic (71% and 13%, respectively) or who had atypical
chest pain (13% and 3%, respectively). No one had
coronary revascularization performed between tests
(median, 47 days), but 10 did so<60 days after testing.
The overall results did not differ with the inclusion or
exclusion of these 10 patients, and no statistical
interaction was observed between SPECT and ETT
variables on patients’ outcome (all, p > 0.20). Testing
sequence also had no effect on outcome on univariate
(p¼ 0.66) or multivariate (p ¼ 0.69) analysis. For these
reasons, the data on all 988 patients are presented, of
whom 946 (96%) had adequate follow-up.
ELECTRON BEAM COMPUTED TOMOGRAPHY. CACS
assessment was performed using electron beam CT(Imatron C-150, Imatron, San Francisco, Cal-
ifornia). Coronary artery calciﬁcation was
deﬁned as a lesion of >130 Hounsﬁeld units,
with an area equal to 3 pixels. CACS was
calculated using the standard Agatston
criteria, and patients were classiﬁed as hav-
ing normal (#10), mild (11 to 100), moderate
(101 to 400), or severe (>400) calciﬁ-
cation (10). None of the patients underwent
CT angiography as a part of their CACS
procedure.
EXERCISE TREADMILL TESTING. Patients
underwent symptom-limited ETT using the
standard Bruce protocol. Ischemia was
deﬁned as $1 mm of ST-segment depression
occurring >80 ms after the J point. ETT was
interpreted by investigators blinded to
the CACS and SPECT results. High and low
risk were deﬁned as the presence and absence of
ischemia, respectively. DTS was calculated and clas-
siﬁed as low ($5), intermediate (4 to –10), or high
(#–11) risk (8). Risk on the basis of peak exercise
capacity was classiﬁed as low (>8 METs), intermedi-
ate (5 to 8 METs), or high (<5 METs) (6).
SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY.
SPECT was performed according to standard guide-
lines (10). Images were visually interpreted in all 3
standard projections, as previously reported, along
with gated and raw image data to assess for study
normalcy/abnormalcy and perfusion defect revers-
ibility (10).
CLINICAL ASSESSMENT AND PATIENT FOLLOW-UP.
Baseline demographic characteristics, symptom sta-
tus, and medical history were prospectively recorded
during interviews with experienced technical
staff at the time of CACS testing. Patients were
stratiﬁed, on the basis of standard FRS criteria, into
categories of low (<6%), intermediate (6% to 20%),
or high (>20%) 10-year risk for cardiac events (11).
Because absolute cholesterol and blood pressure
measurements were not available, we calculated the
FRS using conservative deﬁnitions of hyperlipidemia
(cholesterol 200 to 239 mg/dl) and hypertension (sys-
tolic blood pressure 140 to 159 mm Hg) as previously
reported (10).
Follow-up was prospectively performed using
questionnaires, telephone interviews, and review
of medical records (median follow-up: 6.9 years;
25th to 75th percentile: 4.7 to 8.8 years), with events
corroborated as previously reported (10). Cardiac
events were deﬁned as a composite of cardiac death,
nonfatal myocardial infarction (MI), and the need for
tomo
TABLE 1 Baseline Demographic Characteristics, CACS, and Exercise Test Results in
All Patients With Follow-Up and on the Basis of Events
All Patients
With Follow-Up
(N ¼ 946)
Subgroups
Without
Events
(n ¼ 840)
With
Event
(n ¼ 106) p Value
Age, yrs 57.5  9.3 57.2  9.3 59.6  8.9 0.01
Male 712 (75.3) 623 (74.2) 89 (84.0) 0.03
Cardiac risk factors
Diabetes 91 (9.6) 75 (8.9) 16 (15.1) 0.05
Hypertension 469 (49.6) 402 (47.9) 67 (63.2) 0.004
Hyperlipidemia 540 (57.1) 470 (56.0) 70 (66.0) 0.06
Smoking 440 (46.5) 386 (46.0) 54 (50.9) 0.35
Family history for CAD 407 (43.0) 369 (43.9) 38 (35.9) 0.12
$2 cardiac risk factors 645 (68.2) 567 (67.5) 78 (73.6) 0.06
FRS
Score 11.1  6.5 10.8  6.4 13.3  6.5 0.0002
Risk 0.02
Low (<6%) 160 (16.9) 149 (17.7) 11 (10.4)
Intermediate (6%–20%) 655 (69.2) 583 (69.4) 72 (67.9)
High (>20%) 131 (13.9) 108 (12.9) 23 (21.7)
Atypical chest pain 156 (16.5) 148 (17.6) 8 (7.6) 0.008
SPECT
Abnormal 103 (10.9) 75 (8.9) 28 (26.4) <0.0001
Normal 843 (89.1) 765 (91.1) 78 (73.6) <0.0001
CACS
Score
Mean  SD 314  514 276  462 622  748 <0.0001
Median (IQR) 118 (14–401) 104 (7–325) 412 (118–743) <0.0001
CACS 0 167 (17.7) 160 (19.1) 7 (6.6) 0.001
Risk <0.0001
Low (CACS 0–10) 229 (24.2) 219 (26.1) 10 (9.4)
Intermediate (CACS 11–100) 205 (21.7) 192 (22.9) 13 (12.3)
Intermediate (CACS 101–400) 274 (29.0) 246 (29.3) 28 (26.4)
High (CACS >400) 238 (25.2) 183 (21.8) 55 (51.9)
ETT variables
Peak heart rate 153  17 154  16 148  18 0.0003
Peak systolic BP 178  26 178  26 182  29 0.09
Peak diastolic BP 82  15 81  15 85  17 0.03
Rate pressure product 27,253  4,911 27,291  4,809 26,948  5,665 0.5
Ischemic exercise ECG 116 (12.3) 92 (11.0) 24 (22.6) 0.001
DTS
Score 8.4  3.9 8.6  3.8 6.8  4.4 <0.0001
Risk 0.02
Low ($5) 795 (84.0) 715 (85.1) 80 (75.5)
Intermediate (4 to 10) 143 (15.1) 119 (14.2) 24 (22.6)
High (#11) 8 (0.9) 6 (0.7) 2 (1.9)
Peak exercise capacity
METs 10.4  3.2 10.5  3.2 9.5  2.8 0.005
Risk 0.06
Low (>8 METs) 707 (74.7) 636 (75.7) 71 (67.0)
Intermediate (5–8 METs) 210 (22.2) 177 (21.1) 33 (31.1)
High (<5 METs) 29 (3.1) 27 (3.2) 2 (1.9)
Values are mean  SD for continuous variables, medians (interquartile ranges) if continuous variables were
skewed, and n (%) for categorical variables. p Values on the basis of chi-square or the Fisher exact test for
categorical variables and t-test or Mann-Whitney U test for continuous variables for comparisons between
patients with and without follow-up, or between patients with and without events.
BP¼ blood pressure; CACS¼ coronary artery calcium score; CAD¼ coronary artery disease; DTS ¼ Duke treadmill
score; ECG ¼ electrocardiographic; ETT ¼ exercise treadmill test; FRS ¼ Framingham risk score; METs ¼ metabolic
equivalents of task; SPECT ¼ single-photon emission computed tomography.
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136coronary revascularization following the develop-
ment of symptomatic CAD (10).
STATISTICAL ANALYSIS. Baseline characteristics
were summarized according to clinical follow-up and
cardiac event status. All data are presented as mean 
SD for continuous variables, median and interquartile
range for skewed continuous variables, and number
and percentage for categorical variables. The chi-
square or Fisher exact test (for categorical variables)
and the Student t test or Mann-Whitney U test (for
continuous variables) were used to compare data
from patients with and without follow-up and those
with and without events and to determine associa-
tions between CACS severity and FRS categories, ETT,
and SPECT variables.
Kaplan-Meier survival curves were calculated in
strata deﬁned by CACS risk categories and those of
FRS, ETT, and SPECT variables. The date on which
CACS was performed deﬁned time 0. Two-sided log-
rank tests deﬁned signiﬁcance. To explore risk factors
that could be associated with total cardiac events and
cardiac death and/or MI, a univariate Cox proportional
hazards model was initially applied, using clinical,
CACS, ETT, and SPECT variables. CACS was trans-
formed to the natural logarithm to stabilize the vari-
ance before the analysis. Multivariate analysis was
then performed by entering into the model a set of
variables that were considered signiﬁcant on univari-
ate analysis (p < 0.10). There was no signiﬁcant inter-
action between sex and other risk factors, or between
SPECT and CACS/ETT variables. The proportionality
assumption of Cox models was veriﬁed by including
time-dependent interaction of each covariate with the
event time in the model. There was no violation of this
assumption with any covariate. A separate analysis
was performed on data from 824 patients (87% of the
total cohort) currently considered acceptable candi-
dates for functional testing on the basis of recent
appropriate use criteria (i.e., intermediate to high FRS
risk and/or chest pain symptoms) (4). These patients
were deﬁned as the appropriate use cohort.
Area under the receiver-operating characteristic
curve (AUC) and global chi-square analyses deter-
mined the incremental value of CACS over FRS, and
functional variables for predicting events. AUCs were
calculated from logistic regression models and
compared. The increased discriminative value of
CACS was examined with absolute integrated
discrimination improvement (IDI), relative IDI, and
net reclassiﬁcation improvement (NRI) methods (12).
The p value for relative IDI was obtained using a
permutation test. The NRI requires that there exist a
priorimeaningful risk categories (we used <6%, 6% to
20%, and >20% for the risk for cardiac events).
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137All analyses were performed with STATA version 12
(StataCorp LP, College Station, Texas). Statistical sig-
niﬁcance was deﬁned as 2-tailed p < 0.05 for all tests.
The NRIs calculated with STATA may have been lower
than if they had been calculated using SAS.
RESULTS
BASELINE CHARACTERISTICS. The mean age of the
overall study population was 57.5  9.3 years, and the
median was 57 years (interquartile range: 51 to 64
years) (Table 1). Most of the patients (75.3%) were
male, and 95% had 1 or more risk factors for CAD
(68.2% had 2 or more risk factors). Nearly 10% of pa-
tients were diabetic, 43.0% had a family history of
CAD, and 16.5% had atypical chest pain symptoms.
Most patients had an intermediate or high FRS
(83.1%).
Most patients had no ETT ischemia (87.7%), ach-
ieved >8 METs (74.7%), had a low DTS (84.0%), and
had a normal SPECT (89.1%). The concordance be-
tween ETT and SPECT was high (82%), with most
patients having normal (785/988 [80%]) or abnormal
(24/988 [2%]) results on both tests. The median CACSTABLE 2 Relationship Between CACS Risk Category and Framingham
Subsequent Reclassiﬁcation on the Basis of CACS
CAC
Low
(0–10)
Intermedia
(11–100)
FRS risk
Low (n ¼ 160) 70 (43.8) 48 (30.0
Intermediate (n ¼ 655) 153 (23.4) 139 (21.2)
High (n ¼ 131) 6 (4.6) 18 (13.7)
p Value
ETT
No Ischemia (n ¼ 830) 202 (24.3) 184 (22.2)
Ischemia (n ¼ 116) 27 (23.3) 21 (18.1)
p Value
SPECT
Normal (n ¼ 843) 225 (26.7) 198 (23.5)
Abnormal (n ¼ 103) 4 (3.9) 7 (6.8)
p Value
Peak exercise capacity risk
Low (>8 METs; n ¼ 707) 165 (23.3) 166 (23.5)
Intermediate (5–8 METs; n ¼ 210) 56 (26.7) 34 (16.2)
High (<5 METs; n ¼ 29) 8 (27.6) 5 (17.2)
p Value
DTS risk
Low (n ¼ 795) 190 (23.9) 187 (23.5)
Intermediate (n ¼ 143) 38 (26.6) 17 (11.9)
High (n ¼ 8) 1 (12.5) 1 (12.5)
p Value
Values are n (%).
Abbreviations as in Table 1.was 118, with approximately one-fourth of patients in
each CACS category. A CACS of 0 was present in 167
patients (17.7%). The only signiﬁcant differences
between patients with and without follow-up were
mean age (57.5  9.3 years vs. 50.8  10.3 years;
p < 0.0001) and mean FRS (11.1  6.5 vs. 7.9  4.1; p ¼
0.002), respectively.
LONG-TERM CARDIAC EVENTS. There were 106
patients with at least 1 cardiac event (11.2%), for an
annualized event rate (AER) of 1.6% (cardiac death,
n ¼ 17; nonfatal MI, n ¼ 16; and need for coronary
revascularization, n ¼ 73). The subgroup of patients
with at least 1 event had a higher mean FRS and CACS,
more frequently had ETT ischemia or an abnormal
SPECT, and had a lower mean DTS and exercise ca-
pacity (in METs) than did the subgroup without
events (Table 1). Most patients with events had a
CACS >100 (78.3%) or >400 (51.9%). All 10 patients
(9.4%) with an event after a low-risk CACS also had a
normal SPECT. Conversely, 22.6% and 26.4% of pa-
tients with events had ETT ischemia and/or an
abnormal SPECT, respectively, which minimally
increased to 29% and 34% in those with a CACS >400.Risk Score, Exercise Treadmill Test, and SPECT Risk Categories and
S Risk Category
Reclassiﬁed by CACS
te Intermediate
(101–400)
High
(>400)
) 26 (16.3) 16 (10.0) 90 (56)
199 (30.4) 164 (25.0) 317 (48)
49 (37.4) 58 (44.3) 73 (56)
<0.0001 Total 480/946 (50.7)
246 (29.6) 198 (23.9) 628 (76)
28 (24.1) 40 (34.5) 27 (23)
0.09 Total 655/946 (69.2)
243 (28.8) 177 (21.0) 618 (73.3)
31 (30.1) 61 (59.2) 4 (4)
<0.0001 Total 622/946 (65.8)
204 (28.9) 172 (24.3) 542 (77)
60 (28.6) 60 (28.6) 116 (55)
10 (34.5) 6 (20.7) 23 (79)
0.34 Total 681/946 (72.0)
231 (29.1) 187 (23.5) 605 (76)
43 (30.1) 45 (31.5) 83 (58)
0 6 (75.0) 2 (25)
0.001 Total 690/946 (72.9)
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138A high risk on DTS or poor exercise capacity was
observed in 1.9% of patients with events.
RISK RECLASSIFICATION WITH CACS: FRS, ETT, AND
SPECT VARIABLES. Mean CACS was signiﬁcantly
increased within increasing FRS risk categories (low:
109  192 [median: 21]; intermediate: 318  523 [me-
dian: 122]; and high: 553  621 [median: 336]; p <
0.0001). The addition of CACS to FRS reclassiﬁed
50.7% of patients with similar results when CACS was
added to any of the functional ETT or SPECT variables
(Table 2). CACS signiﬁcantly increased overall NRI
(30.2%), IDI (3.5%), and relative IDI (285%) when
added to the FRS (all, p < 0.0001), and this was
observed across all FRS categories as well as in the
appropriate use cohort (Table 3). Similarly, NRI, IDI,
and relative IDI were signiﬁcantly increased in all
patients when CACS was added to models containing
FRS and any SPECT or ETT variable (all, p < 0.0001).
Importantly, this ﬁnding occurred within each FRS
category in addition to the appropriate use cohort
(Table 3). Whereas no functional variables reclassiﬁed
risk in the low-risk FRS group, CACS reclassiﬁed risk
in this group beyond the FRS and in all models con-
taining FRS and any of the functional variables.
UNIVARIATE AND MULTIVARIATE PREDICTORS OF
LONG-TERM EVENTS. Univariate risk predictors of all
events included FRS, an abnormal SPECT and ETT
ischemia, increasing CACS, and decreasing METs and
DTS. On multivariate analysis, all signiﬁcant ﬁndings
were retained, except for the FRS (Table 4). Similar
ﬁndings were observed in the appropriate use cohort
(Table 4). When the models estimated cardiac death
and/or MI, only decreasing DTS and increasing CACS
severity added to the multivariate model (Table 5).
In the appropriate use cohort, decreasing METs,
decreasing DTS, and increasing CACS severity were
the only multivariate predictors of the risk for cardiac
death and/or MI (Table 5).
LONG-TERM CARDIAC EVENTS ON THE BASIS OF
FRS, CACS, AND ETT RESULTS. Cardiac event rates
were signiﬁcantly increased with increasing FRS
category (Figure 1A), presence of ETT ischemia
(Figure 1B), increasing CACS severity (Figure 1C), and
decreasing DTS. AERs were signiﬁcantly increased
with increasing categories of risk on FRS (low: 0.97%
[95% CI: 0.54% to 1.75%]; high: 2.60% [95% CI: 1.73%
to 3.92%]; p ¼ 0.02) (Figure 1A) and DTS (low: 1.49%
[95% CI: 1.2% to 1.86%]; intermediate: 2.7% [95% CI:
1.81% to 4.02%]; and high: 4.21% [95% CI: 1.05% to
16.85%]; p ¼ 0.008) and between the subgroup
without versus that with ETT ischemia (without:
1.48% [95% CI: 1.19% to 1.84%] vs. with: 3.11% [95%
CI: 2.08% to 4.64%]; p ¼ 0.001) (Figure 1B). CACS best
TABLE 4 Univariate and Multivariate Predictors of All Cardiac Events
Univariate Multivariate*
HR 95% CI p Value HR 95% CI p Value
All patients (n ¼ 946)
Increasing FRS 1.04 1.02–1.07 <0.0001 1.01 0.98–1.04 0.66
Atypical chest pain 0.45 0.22–0.93 0.03 0.60 0.29–1.25 0.17
Abnormal SPECT 3.25 2.11–5.01 <0.0001 1.83 1.15–2.90 0.01
ETT ischemia 2.06 1.31–3.25 0.002 1.70 1.07–2.70 0.02
Decreasing METs 1.10 1.04–1.17 0.002 1.11 1.04–1.18 0.002
Decreasing DTS 1.10 1.06–1.14 <0.0001 1.07 1.03–1.11 <0.0001
Log(CACS þ 1) 1.39 1.25–1.56 <0.0001 1.29 1.15–1.49 <0.0001
Appropriate use cohort (n ¼ 824)
Increasing FRS 1.04 1.02–1.07 0.001 1.01 0.98–1.04 0.56
Atypical chest pain 0.42 0.20–0.86 0.02 0.62 0.30–1.30 0.21
Abnormal SPECT 3.32 2.14–5.16 <0.0001 1.99 1.25–3.19 0.004
ETT ischemia 2.08 1.30–3.32 0.002 1.76 1.09–2.83 0.02
Decreasing METs 1.10 1.03–1.18 0.004 1.17 1.04–1.20 0.002
Decreasing DTS 1.10 1.05–1.14 <0.0001 1.07 1.03–1.11 <0.0001
Log(CACS þ 1) 1.40 1.24–1.58 <0.0001 1.29 1.13–1.46 <0.0001
*Multivariate model included FRS, atypical chest pain, abnormal SPECT, log(CACS þ 1), and DTS or ETT Ischemia
and METs.
HR ¼ hazard ratio; other abbreviations as in Table 1.
TABLE 5 Univariate and Multivariate Predictors of Cardiac Death and MI
Univariate Multivariate*
HR 95% CI p Value HR 95% CI p Value
All patients (n ¼ 946)
Increasing FRS 1.07 1.03–1.11 0.001 1.03 0.99–1.08 0.17
Atypical chest pain 0.36 0.09–1.51 0.16 – – –
Abnormal SPECT 2.00 0.83–4.86 0.12 – – –
ETT ischemia 1.55 0.64–3.75 0.33 – – –
Decreasing METs 1.13 1.01–1.26 0.04 1.11 0.98–1.25 0.10
Decreasing DTS 1.10 1.03–1.18 0.005 1.08 1.01–1.15 0.03
Log(CACS þ 1) 1.51 1.22–1.88 <0.0001 1.41 1.13–1.76 0.002
Appropriate use cohort (n ¼ 824)
Increasing FRS 1.06 1.02–1.11 0.005 1.03 0.98–1.08 0.19
Atypical chest pain 0.31 0.07–1.31 0.11 – – –
Abnormal SPECT 1.90 0.78–4.65 0.16 – – –
ETT ischemia 1.60 0.65–3.91 0.31 – – –
Decreasing METs 1.14 1.00–1.28 0.04 1.15 1.01–1.30 0.04
Decreasing DTS 1.10 1.03–1.18 0.006 1.09 1.01–1.16 0.02
Log(CACS þ 1) 1.50 1.19–1.90 0.001 1.41 1.12–1.79 0.004
*Multivariate model included FRS, log(CACS þ 1), DTS, and METs.
MI ¼ myocardial infarction; other abbreviations as in Table 1.
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139deﬁned risk, with a very low AER of 0.62% in patients
with a CACS #10 (0.59% if CACS ¼ 0), which was
increased to 3.73% in those with a CACS >400
(Figure 1C).
LONG-TERM CARDIAC EVENTS IN LOW ETT/ SPECT
RISK GROUPS ON THE BASIS OF CACS SEVERITY.
Event rates were compared across CACS severities
within low-risk ETT and SPECT subgroups (Table 6,
Figure 2). A CACS #10 deﬁned a hazard ratio (HR) of 1.
In patients without ETT ischemia, AER was increased
from 0.56% with CACS #10 to 3.15% with CACS >400
(p < 0.0001) (Figure 2A), with an HR of 5.25 with CACS
>400 (Table 6). Time point analysis showed separa-
tion of event curves at year 4 after initial testing. The
AER in the subgroup with a low-risk DTS was
increased from 0.58% with CACS #10 to 3.00% with
CACS >400 (p < 0.0001), with separation of event
curves at year 5 (Figure 2B) and an HR of 5.13 with
CACS >400 (Table 6). The AER (95% CI) in the sub-
group achieving >8 METs was increased from 0.52%
(0.23% to 1.16%) with CACS #10, to 1.06% (0.60% to
1.86%) with CACS 11 to 100, to 1.15% (0.70% to 1.87%)
with CACS 101 to 400, to 3.41% (2.47% to 4.70%) with
CACS >400 (p < 0.0001), with separation of event
curves at year 3 (p ¼ 0.005) and an HR of 6.51 with
CACS >400 (Table 6). In patients with a normal
SPECT, HR was increased to 4.92 with CACS >400
(p < 0.0001) (Table 6). The HR for any event also
increased in the appropriate use cohort in the sub-
group that had a CACS >400 (normal ETT: 5.17; low-
risk DTS: 4.85; >8 METs: 6.51; and normal SPECT:
4.12) (Table 6).
INCREMENTAL PROGNOSTIC VALUE OF CACS OVER
FRS AND ETT VARIABLES. Global chi-square in-
creased signiﬁcantly versus the FRS alone with the
addition of METs (14.68) and ETT ischemia (16.16)
information (Figure 3A). The addition of CACS to
the clinical model increased the global chi-square
from 11.72 to 45.33 (p < 0.0001). When CACS was
added to the FRS and any ETT variable, global chi-
square was markedly increased, whereas minor,
albeit signiﬁcant, increases were observed when
METs and ETT ischemia information was added to the
FRS þ CACS model.
AUC demonstrated the largest improvement when
CACS was added to the FRS variable (from 0.63
to 0.70; p ¼ 0.01) versus the ETT variable (from 0.63
to 0.65; p ¼ 0.3) (Figure 3B) or SPECT (from 0.63 to
0.67; p ¼ 0.02) (Figure 3C). AUC was increased with
the addition of CACS to the FRS þ ETT variables
(from 0.65 to 0.71; p ¼ 0.01), with a numerical but
statistically nonsigniﬁcant improvement with the
addition of CACS to FRS þ SPECT (from 0.67 to 0.71;p ¼ 0.08). The addition of ETT or SPECT did not
improve the model of CACS þ FRS (both, from 0.70
to 0.71; p ¼ 0.15).
DISCUSSION
We followed up a large-scale, generally asymptom-
atic cohort of men and women for up to a decade in
order to assess the utility of CACS ﬁndings in
FIGURE 1 Long-Term Event Rates
Event rates on the basis of Framingham risk score (A), exercise treadmill test (ETT) ischemia (B), and coronary artery calcium score (CACS) (C). Events were cardiac death,
nonfatal myocardial infarction, and the need for coronary revascularization.
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140relation to clinical, ETT, and SPECT results for pre-
dicting long-term outcome. Other studies have
compared the prognostic values of either ETT (5–8),
CACS (1,2,10,11), or SPECT (10,13) alone or in relation
to FRS. However, our study is the ﬁrst to uniquely
examine the interrelationship of multiple testing
modalities in predicting long-term outcome (mean
follow-up: 6.9 years) in patients for whom current
appropriate use criteria generally support functional
testing—and also in low-risk, asymptomatic patients
in whom functional testing is not recommended (4).
This ﬁnding was achieved through a rigorous statis-
tical analysis using NRI, IDI, relative IDI, global chi-
square, and AUC methods. Although the overall
event rate in the study cohort was relatively low
(1.6% per year), as might be expected in generallyasymptomatic patients, the population was hetero-
geneous as to their risk, which afforded identifying
signiﬁcant differences in risk prediction among
testing strategies. Importantly, the AERs observed in
our population closely tracked the expected event
rates on the basis of a conventional FRS model of
low (0.97%), intermediate (1.68%), and high (2.60%)
risk.
Our results demonstrate that CACS has incremental
long-term prognostic value over and above the FRS
and across all FRS categories. This ﬁnding was also
observed in patients at low clinical risk who are
currently not considered appropriate candidates for
CACS testing. We also report relative superiority of
CACS over all ETT and SPECT variables for identifying
high- and low-risk subgroups and even among
TABLE 6 Relative Long-Term Risk of Total Cardiac Events on the Basis of CACS Severity
Cohort/CACS Severity
Normal Stress ECG
(n ¼ 830)
Low-Risk DTS
(n ¼ 795)
METs >8
(n ¼ 707)
Normal SPECT
(n ¼ 843)
HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value HR 95% CI p Value
All patients
Low (CACS 0–10) (ref) 1.00 1.00 1.00 1.00
Intermediate (CACS 11–100) 1.90 0.77–4.69 0.16 1.75 0.71–4.31 0.22 2.06 0.77–5.49 0.15 1.63 0.71–3.76 0.25
Intermediate (CACS 101–400) 2.44 1.07–5.56 0.03 2.70 1.20–6.09 0.02 2.23 0.86–5.77 0.10 1.71 0.78–3.74 0.18
High (CACS >400) 5.25 2.38–11.55 <0.0001 5.13 2.31–11.41 <0.001 6.51 2.66–15.94 <0.0001 4.92 2.35–10.31 <0.0001
Appropriate use cohort
Low (CACS 0–10) (ref) 1.00 1.00 1.00 1.00
Intermediate (CACS 11–100) 1.60 0.55–4.65 0.38 1.46 0.50–4.22 0.49 1.93 0.58–6.42 0.28 1.32 0.51–3.44 0.57
Intermediate (CACS 101–400) 2.67 1.07–6.64 0.04 2.92 1.18–7.20 0.02 2.67 0.88–8.07 0.08 1.71 0.74–3.96 0.21
High (CACS >400) 5.17 2.13–12.55 <0.0001 4.85 1.98–11.85 0.001 6.51 2.25–18.83 0.001 4.12 1.84–9.20 0.001
Adjusted for FRS and METs in normal stress ECG model. Adjusted for FRS in low-risk DTS model. Adjusted for FRS and ETT ischemia in METs >8 model.
Abbreviations as in Tables 1 and 4.
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141patients in whom functional testing is currently
considered appropriate. This ﬁnding was also true for
the >80% of total patients who had low-risk ETT and
SPECT ﬁndings. Our results reafﬁrm that functional
testing is inappropriate in clinically low-risk patients
but also demonstrate that CACS enhances risk
prediction in those in whom functional testing is
currently considered an appropriate initial strategy
(3,4,9). The added value of CACS beyond clinical,
ETT, and SPECT information was consistent across 5
different statistical methods.
In a multimodality world where there are many
options for evaluating asymptomatic patients at risk
for CAD, our results support the selection of CACS,FIGURE 2 Long-Term Event Rates on the Basis of CACS Results in L
Event rates on the basis of CACS results in patients without ETT ischem
in Figure 1.over ETT and SPECT, as the practical initial test for
accurately predicting long-term cardiovascular risk in
both men and women when used in conjunction with
a standard clinical assessment. The cost effectiveness
of this approach warrants future study.
CACS FOR PREDICTING RISK. Many studies have
demonstrated the value of CACS in predicting
outcome (1,2). Recent evidence suggests that the
addition of CACS to clinical information reﬁnes risk
stratiﬁcation in a substantial percentage of patients
(11,14). We observed a signiﬁcant increase in both
global chi-square (from 11.7 to 45.3) and in AUC
(from 0.63 to 0.70) when CACS was added to the FRS.ow-Risk ETT Groups
ia (A) and low ($5) Duke treadmill score (DTS) (B). Events as in Figure 1. Abbreviations as
FIGURE 3 Incremental Prognostic Value of CACS, ETT, and SPECT Variables
A
B C
Incremental prognostic value of CACS and ETT variables in relation to Framingham risk score (FRS) by global chi-square (A), and area under the
receiver-operating characteristic curve (AUC) when incorporating FRS and CACS with either ETT variables (B) or stress myocardial perfusion
single-photon emission computed tomography (SPECT) (C). Events as in Figure 1. Abbreviations as in Figures 1 and 2.
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142A comparable increase in AUC of 0.07 (from 0.68
[FRS] to 0.75 [FRS þ CACS]) was also observed in the
trial by the Heinz Nixdorf Recall Study Investigative
Group (11). In our study, CACS reclassiﬁed risk even
among those considered at low annual risk despite a
small sample size of 160 patients. The AER in the low
FRS group was 0.97%. However, by adding CACS, the
NRI in this group was more than 40%, with a 15-fold
difference in event rates (0.37% with CACS #10 vs.
5.63% with CACS >400). A low FRS was seen in 17% of
our patients—consistent with the 22% prevalence in
the Heinz Nixdorf trial (11). In a recent study of
44,000 asymptomatic patients followed up for 5
years, CACS predicted all-cause mortality even among
those with no signiﬁcant CAD risk factors (15).
Consistent with others, we also demonstrate the
value of CACS in reclassifying risk in intermediate
(NRI: 29%) and high (NRI: 35%) FRS groups (11,14).ETT FOR PREDICTING RISK. Current guidelines and
appropriate use criteria generally support performing
ETT in intermediate- and high-risk asymptomatic
patients and in those with symptoms suggestive of
CAD (3,4,9). Most of our patients (87%) would have
been considered appropriate candidates for func-
tional testing on the basis of the current guidelines.
Studies have demonstrated exercise capacity as a
strong predictor of survival in asymptomatic men and
women (6,7) and DTS in primarily symptomatic pa-
tients with known CAD (8). A recent study in 5,638
asymptomatic women demonstrated a signiﬁcant
reduction in total and cardiac mortality using the
DTS, but exercise capacity primarily deﬁned risk
rather than symptoms or severity of ETT ischemia (7).
This ﬁnding may not be surprising because women
have a wide variety of cardiac symptoms and frequent
false-positive ETTs (9).
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143We compared CACS to conventional ETT variables
of ischemia, DTS, and peak METs. The AER on the
basis of CACS alone varied 6-fold, from a low of 0.62%
(CACS #10) to a high of 3.73% (CACS >400) (p <
0.0001). Conversely, the AERs within the low-risk
DTS (1.49%), METs (1.50%), and ETT ischemia
(1.48%) subgroups were similar to that of the entire
population (1.62%), indicating little beneﬁt of a low-
risk ETT result. HRs were increased by approxi-
mately 5-fold when these low-risk patients were
further stratiﬁed by CACS. This ﬁnding was also true
in the appropriate use cohort subgroup with low-risk
ETT ﬁndings, thereby bringing into question the
utility of current appropriate use guidelines that
support ETT testing in such patients (Table 6). ETT
variables also added little incremental prognostic in-
formation to FRS on the basis of global chi-square or
AUC analysis. Our results differ from those from a
recent study in 710 men with CACS >100, in which
patients who achieved >10 METs had a similar low
event rate irrespective of CACS—but with only a 3.5-
year follow-up (16). In our study, the incremental
beneﬁt of CACS over ETT occurred only at 4 or more
years after initial testing, emphasizing the impor-
tance of long-term follow-up. Thus, the “warranty
period” of a low-risk ETT is relatively short, espe-
cially when viewed from the anticipated 25-year
additional life expectancy of the typical middle-
aged, asymptomatic patient.
SPECT FOR PREDICTING RISK. Stress SPECT iden-
tiﬁes low- and high-risk asymptomatic patients, but
an abnormal result is observed in a small minority of
patients (17,18). We previously published that a
normal SPECT has a short “warranty period” and
limited long-term prognostic value compared with
CACS (10). In the present study, SPECT was a predic-
tor of total cardiac events (Table 4) but did not predict
cardiac death and/or MI in all patients or speciﬁcally
in the appropriate use cohort (Table 5). This ﬁnding is
best illustrated in the w90% of patients who had a
normal SPECT, in whom event rates increased by
approximately 4- to 5-fold as CACS increased from
low to high risk (Table 6). This ﬁnding was true in all
patients as well as in the appropriate use cohort, in
whom SPECT is currently recommended (4). Ulti-
mately, 74% of patients with events had normal
SPECT results and would not have warranted further
testing under the current guidelines. SPECT imaging
appears to be the most appropriate study in the small
minority of patients with severe CACS, who are most
likely to have stress-induced ischemia (3,4,10,13).
CLINICAL IMPLICATIONS. Noncontrast CT is a rapid,
simple test for calculating CACS; has nocontraindications; requires no patient preparation; is
performed on conventional CT systems; incurs little
radiation exposure; is relatively inexpensive
compared with ETT; and is applicable to the popula-
tion of patients currently referred for ETT testing who
are generally healthier and are more likely to have
atypical symptoms versus those undergoing phar-
macological stress testing. CACS severity is directly
related to the extent of coronary atherosclerosis,
whereas ETT and SPECT can assess only advanced
atherosclerotic plaque resulting in ﬂow-limiting cor-
onary stenosis. The JUPITER (Justiﬁcation for the Use
of Statins in Prevention: an Intervention Trial Eval-
uating Rosuvastatin) investigators (19) recently re-
ported a 63% risk reduction with intensive treatment
of hyperlipidemia in asymptomatic patients with high
C-reactive protein levels. The MESA (Multi-Ethnic
Study of Atherosclerosis) investigators matched their
patients to those in JUPITER and demonstrated
similar results using CACS (20). The ﬁndings from
these studies and 1 other (21) reinforce the potential
therapeutic beneﬁt of identifying early atheroscle-
rotic disease using CACS. On the basis of our data,
there appears to be a 3- to 4-year window of oppor-
tunity to treat patients aggressively before a signiﬁ-
cant increase in the risk for cardiac events.
STUDY LIMITATIONS. First, this was not an epide-
miological study, so it comes with unavoidable
selection bias. After an abnormal CACS, ETT SPECT
was recommended, which probably explains why
a large proportion of our cohort had a CACS
>100. However, many of our patients with a CACS
#10 also had SPECT because at the time of this study
it was not known what CACS cutoff would result in an
abnormal SPECT. This registry was conducted before
guidelines limiting functional testing to patients with
CACS >400, allowing us to study those with broad
CACS values, including 17% with a CACS of 0. Second,
CACS results were available to patients and referring
physicians, who could have initiated life-style
changes and/or pharmacological interventions that
might have reduced the prevalence of cardiac events.
However, this potential occurrence would be ex-
pected to have biased our study against observing a
relationship between CACS and events. Third,
although this was a single-center study, our cohort
was similar to those of multicenter trials (1,2,11,14),
and our follow-up time was considerably longer.
CONCLUSIONS
CACS signiﬁcantly improved long-term risk stratiﬁ-
cation beyond FRS, ETT, and SPECT results across the
entire spectrum of clinical risk and, importantly, even
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144among patients who are currently considered appro-
priate candidates for functional testing or who have
low-risk functional test results. CACS should be
selected as the initial test for assessing cardiac risk in
middle-aged men and women irrespective of their
clinical risk proﬁle.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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